|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.28 HKD | +4.79% |
|
+13.10% | -10.14% |
| Apr. 25 | Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation | MT |
| Apr. 24 | Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary | CI |
Abbisko Cayman Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 19.06 million. Net loss was CNY 431.58 million compared to CNY 495.61 million a year ago.
Basic loss per share from continuing operations was CNY 0.67 compared to CNY 0.8 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.14% | 245M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
ABBISKO CAYMAN LIMITED 
